Advancing reproductive health technologies.

Through cell engineering, Gameto is developing an ecosystem
of therapeutics to support modern women throughout
their reproductive journeys.


Context


Women are born with a finite number of eggs–all of the eggs they will ever have. As women age, the number and quality of these eggs decline throughout their lifetime, causing a number of problems with the female reproductive system. Notably, the relative decline leads to infertility, and the absolute decline causes menopause.

This decline is not a biological imperative. Only humans and four types of whales even experience menopause. With few species experiencing this decline in ovarian health, studying the female reproductive system is challenging.

Unfortunately, Women's reproductive health is an underdeveloped area within the healthcare industry. Despite a growing global infertility crisis, fertility therapies have remained largely unimproved since inception decades ago. To make matters worse, inclusion of women in clinical trials was not required until 1993. Therefore, many modern-day products are understudied in women resulting in lack of understanding and efficacy, and potentially leading to severe side effects.Gameto is working to fill this gap in the industry with therapies that will not only improve the female reproductive journey, but improve lives.

Platform

Gameto has developed a platform to produce female reproductive cell lines. We use proprietary cell engineering  to generate ovarian cell lines that mimic the functions of reproductive system cells, producing and responding to all hormones.

Our team of engineers is using this platform to build a portfolio of cellular therapeutics for women’s health.

Gameto is currently developing the first application of this platform, Fertilo, which is a technology designed to improve assisted fertility outcomes.

Fertilo
Induced pluripotent stem cells
Cell engineering
Female reproductive cell types
Organoid of the female reproductive system
The platform allows us to generate solutions for the female reproductive system

We are currently focused on improving fertility care outcomes, but what we are currently doing for infertility, we will soon do for drug development, menopause, and much more...

Clinical Applications

Fertilo (lead program)

Designed to improve outcomes of  IVF and other assisted fertility methods

Deovo

Designed to test & develop drugs for ovarian disease

Ameno

Intended to make the medical burden of menopause optional

Relevant Publications:

Fertilo

To improve outcomes of  IVF

Deovo

To test and develop drugs for ovarian disease

Ameno

To make the medical burden of menopause optional

Programs

We are working on applications that address women’s reproductive health, including assisted fertility outcomes, ovarian disease, menopause, and more.